XIPERE Drug Patent Profile

Which patents cover Xipere, and when can generic versions of Xipere launch?

Xipere is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-one patent family members in eighteen countries.

The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xipere

A generic version of XIPERE was approved as triamcinolone acetonide by TARO on October 1^st, 1986.

Summary for XIPERE

International Patents:	81
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	83
Patent Applications:	4,203
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for XIPERE
What excipients (inactive ingredients) are in XIPERE?	XIPERE excipients list
DailyMed Link:	XIPERE at DailyMed

See drug prices for XIPERE

Pharmacology for XIPERE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for XIPERE

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XB	Corticosteroids, moderately potent, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for XIPERE

XIPERE is protected by three US patents and one FDA Regulatory Exclusivity.

Patents protecting XIPERE

FDA Regulatory Exclusivity protecting XIPERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes			Y

International Patents for XIPERE

See the table below for patents covering XIPERE around the world.

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	201590902	СПОСОБЫ И УСТРОЙСТВА, ПРИМЕНЯЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ БОЛЕЗНЕЙ У ЧЕЛОВЕКА
Mexico	360969	MÉTODOS Y DISPOSITIVOS PARA LA ADMINISTRACIÓN DE FÁRMACOS AL TEJIDO OCULAR UTILIZANDO UNA MICROAGUJA. (METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE.)
Japan	2013525022
Israel	286808	מערכת ושיטות להזרקה עינית (Apparatus and methods for ocular injection)
European Patent Office	2563429	APPAREIL POUR L'ADMINISTRATION D'UN MÉDICAMENT À UN TISSU OCULAIRE À L'AIDE D'UNE MICRO-AIGUILLE (DEVICE FOR DELIVERY OF A DRUG TO OCULAR TISSUE USING MICRONEEDLE)
Japan	2020033381	ヒト被験体における眼部障害の処置のための方法およびデバイス (METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS)